Clinical trial
Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive…
NCT00290693 · University of Miami, Other · Completed
Key facts
| NCT number | NCT00290693 |
|---|---|
| Title | Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer |
| Official title | A Multicenter Phase II Study of Capecitabine and Docetaxel for Previously Treated Pancreatic Cancer Patients "CapTere" |
| Lead sponsor | University of Miami, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine, Docetaxel |
| Enrollment | 45 |
| Start date | Jul 1, 2004 |
| Primary completion | Aug 1, 2008 |
| Completion | Jun 1, 2010 |
| First posted | Feb 13, 2006 |
| Last update posted | Dec 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: